Faes Farma’s Q4 15 and FY 15 results came in slightly below our estimates. Q4 15 net sales were up c.9% yoy to €50.8m, primarily driven by Bilastine, new products and the animal nutrition business. Higher other operating income due to milestone payments pushed the total revenue to €54.5m (+15%). While EBIT increased 22% to €7m, primarily on account of excellent cost containment and higher other operating income, net profit was up c.61% to €5.1m, helped by the repayme
29 Apr 2016
Results marginally below expectations but Bilastine flourishing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Results marginally below expectations but Bilastine flourishing
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
29 Apr 2016 -
Author:
Jyoti Prakash -
Pages:
2
Faes Farma’s Q4 15 and FY 15 results came in slightly below our estimates. Q4 15 net sales were up c.9% yoy to €50.8m, primarily driven by Bilastine, new products and the animal nutrition business. Higher other operating income due to milestone payments pushed the total revenue to €54.5m (+15%). While EBIT increased 22% to €7m, primarily on account of excellent cost containment and higher other operating income, net profit was up c.61% to €5.1m, helped by the repayme